GI CANCERS

AI transforms healthcare by personalizing treatment plans and enhancing patient-provider communication, revolutionizing how we approach medical care.

AI transforms cancer treatment by personalizing care and enhancing patient-provider communication, revolutionizing how patients manage their health.

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

Experts discuss the impact of dose escalation in treating neuroendocrine tumors, highlighting recent trials and collaborative research efforts for improved patient outcomes.

Rising early-onset neuroendocrine tumors reveal unique challenges and disparities, highlighting the need for tailored care and research focused on younger patients.

The FDA designates daraxonrasib as an orphan drug for pancreatic cancer, targeting RAS mutations with promising trial results.

A new analysis reveals unique symptom burdens and quality of life challenges in younger patients with neuroendocrine tumors, enhancing tailored care strategies.

GLP-1 receptor agonists show promise in treating various chronic conditions, but potential risks and unanswered questions remain for care of patients with NETs.

Jonathan Strosberg, MD, details findings with 212Pb-DOTAMTATE in patients with gastroenteropancreatic neuroendocrine tumors from the ALPHAMEDIX-02 trial.

A study reveals that obesity and sex significantly influence liver recurrence and survival rates in pancreatic cancer patients post-surgery.

The COMPETE trial reveals ITM-11 significantly improves progression-free and overall survival in patients with gastroenteropancreatic neuroendocrine tumors.

A groundbreaking study reveals 212Pb-DOTAMTATE's promising efficacy and safety in treating advanced gastroenteropancreatic neuroendocrine tumors.

New data reveals VCN-01 enhances survival and response rates in metastatic pancreatic cancer when combined with standard chemotherapy, promising future trials.

Emerging research highlights the rising incidence of early-onset neuroendocrine tumors, revealing unique challenges and symptom burdens in younger patients.

Nivolumab plus ipilimumab shows significant progression-free survival benefits in metastatic colorectal cancer, establishing a new standard of care.

New research compares transarterial embolization and chemoembolization for treating neuroendocrine liver metastases, revealing unexpected safety differences.

Bemarituzumab combined with mFOLFOX6 shows promising overall survival benefits in advanced FGFR2b-overexpressing gastric cancer, despite safety concerns.

Novel therapies, combinations, and investigational treatments are expanding options and show promise in locally advanced metastatic pancreatic cancer.

Zanzalintinib combined with atezolizumab significantly improves overall survival in metastatic colorectal cancer compared to regorafenib, offering new hope for patients.

Telisotuzumab adizutecan shows promising antitumor activity in advanced pancreatic cancer, with manageable safety and significant clinical benefits in a phase 1 study.

Tislelizumab enhances treatment outcomes in esophageal squamous cell carcinoma, showing improved response rates and survival compared to standard chemoradiotherapy.

Sirexatamab combined with bevacizumab shows promise in improving survival for DKK1-high metastatic colorectal cancer patients, according to recent trial results.

Adjuvant therapy shows promise in achieving ctDNA clearance in colorectal cancer patients, correlating with improved disease-free survival outcomes.

The ALPHAMEDIX-02 trial showed promising results for 212Pb-DOTAMTATE in previously treated gastroenteropancreatic neuroendocrine tumors.

The COMPETE trial reveals ITM-11 significantly improves progression-free survival and overall response rates in GEP-NET patients compared with everolimus.